Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edodekin alfa

Next Previous
X
Search
Drug Profile

Edodekin alfa

Alternative Names: CLMF; human interleukin-12; NKSF; Recombinant human interleukin-12; rhIL-12; rHuIL-12; RO 247472; YM 01C

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche; Wistar Institute
  • Developer Bausch Health Companies; Roche
  • Class Adjuvants; Immunotherapies; Interleukins
  • Mechanism of Action Angiogenesis inhibitors; Cytokine stimulants; Immunostimulants; Interferon gamma stimulants; Interleukin stimulants; Natural killer cell stimulants; T lymphocyte stimulants; Tumour necrosis factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Asthma; Bacterial infections; Cancer; Cutaneous T-cell lymphoma; Graft-versus-host disease; Hepatitis B; Hepatitis C; HIV infections; Kaposi's sarcoma; Leishmaniasis; Lymphoma; Malaria; Malignant melanoma; Non-Hodgkin's lymphoma; Renal cancer

Most Recent Events

  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 04 Sep 2006 Discontinued - Phase-I for Asthma in USA (Inhalation)
  • 04 Sep 2006 Discontinued - Phase-I for Asthma in USA (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top